Posted inBiotechnology
Discover Astellas’ differentiated approach to innovation partnerships
As a global life sciences company, Astellas is passionate about partnering to advance life-changing treatments for patients. If you are…
Posted inBiotechnology
Galectin’s MASH treatment reduces varices but fails to hit statistical significance in phase 3 trial
Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people…
Posted inBiotechnology
Applied Therapeutics CEO steps down in wake of FDA rejection, warning letter and investor lawsuit
A turbulent month at Applied Therapeutics is being capped off with the departure of CEO and chair Shoshana Shendelman, Ph.D.,…
Posted inBiotechnology
Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to…
Posted inBiotechnology
Apollomics, after giving up on GlycoMimetics’ leukemia therapy, posts drug’s latest phase 3 fail
The failure of a myeloid leukemia drug in a phase 3 trial in China isn’t a shock to Apollomics, which…
Posted inBiotechnology
Novo Nordisk stock crashes after CagriSema misses phase 3 weight-loss goal
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss…
Posted inBiotechnology
Idorsia’s sale of Tryvio falls behind schedule, but layoffs remain on track
Idorsia’s plans to sell its hypertension drug Tryvio have faced a speedbump, even as the biotech ploughs ahead with around…
Posted inBiotechnology
Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business
Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and…
Posted inBiotechnology
FDA rejects Zealand Pharma’s GLP-2 analog in rare bowel disease
The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel syndrome (SBS), citing…
Posted inBiotechnology
Pyxis Oncology shelves antibody to focus on sole clinical asset, an ADC licensed from Pfizer
Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results…